Newsletters |  My Homepage
All Sources     Medscape     eMedicine     MEDLINE     Drug Reference
Email This
Your Name: 
Your Email: 
Recipient's Email: 
Separate multiple email addresses with commas (Limit is 10).
Optional Message: 
Download This

Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis.

Medscape Newsletters
Sign Up
Sign Up To Receive
Medscape Best Evidence
Key journal articles ranked for newsworthiness and clinical relevance in each specialty, linked to Medline abstracts.

Arthritis Rheum.  2006; 54(10):3205-11 (ISSN: 0004-3591)

Manicourt DH; Azria M; Mindeholm L; Thonar EJ; Devogelaer JP
St. Luc University Hospital and Christian de Duve Institute of Cellular Pathology, Universit?? Catholique de Louvain, Brussels, Belgium.

OBJECTIVE: To evaluate the effects of oral salmon calcitonin (sCT) on Lequesne's algofunctional index scores and on biomarkers of joint metabolism in knee osteoarthritis. METHODS: In this randomized, double-blind trial, patients received either placebo (n = 18), 0.5 mg of sCT (n = 17), or 1 mg of sCT (n = 18) daily for 84 days. Biomarkers included C-telopeptide of type II collagen (CTX-II), type II collagen neoepitope C2C, collagenases (matrix metalloproteinase 1 [MMP-1], MMP-8, and MMP-13), stromelysin (MMP-3), tissue inhibitors of metalloproteinases 1 and 2, and hyaluronan. Statistical analysis included nonparametric tests. RESULTS: A total of 41 patients completed the study (13 in the group receiving 0.5 mg of sCT and 14 in each of the other 2 other groups). Although, on day 84, patients in both the placebo group and the group receiving 1 mg of sCT exhibited a similar significant decrease in pain scores, a significant reduction in the function score was observed only in the 2 sCT groups. On day 84, there was no significant decrease in biomarker levels in the placebo group, whereas significant reductions in the levels of both MMP-3 and hyaluronan were observed in the 2 sCT groups. The group of patients receiving 1 mg of sCT exhibited significant decreases in the levels of CTX-II, C2C, and MMP-13. CONCLUSION: By improving functional disability and by reducing levels of biomarkers that are thought to be predictive of joint space narrowing (and thus cartilage loss), oral sCT at a dose of 1 mg might be a useful pharmacologic agent in human knee OA.

Major Subject Heading(s)Minor Subject Heading(s)CAS Registry / EC Numbers
  • PreMedline Identifier: 17009253
All Sources    Medscape    eMedicine    MEDLINE    Drug Reference
All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.